Table 4.
Multivariate survival analysis (OS and DSS) in the p53 wt/NSMP ProMisE subgroup. L1CAM and established clinicopathological risk factors available (A) preoperatively and (B) postoperatively
| OS | DSS | |||||
|---|---|---|---|---|---|---|
| # of events / n | Hazard ratio (95% CI) | LRT P value | # of events / n | Hazard ratio (95% CI) | LRT P value | |
| A | ||||||
| Age | 41/228 | 16/227 | ||||
| 1.05 (1.03–1.08) | <0.001 | 1.03 (0.98–1.08) | 0.2 | |||
| L1CAM | 41/228 | 16/227 | ||||
| Negative (ref) | — | — | ||||
| Positive | 2.43 (0.99–5.41) | 0.052 | 3.80 (1.10–12.16) | 0.035 | ||
| Tumour grade | 41/228 | 16/227 | ||||
| Grade 1 and 2 (ref) | — | — | ||||
| Grade 3 | 2.70 (1.00–6.40) | 0.049 | 4.97 (1.33–16.55) | 0.019 | ||
| Histology | 41/228 | 16/227 | ||||
| Endometrioid (ref) | — | — | ||||
| Non-endometrioid | 1.29 (0.07–7.45) | 0.8 | 1.54 (0.08–10.00) | 0.7 | ||
| B | ||||||
| Age | 41/228 | 16/227 | ||||
| 1.05 (1.02–1.08) | <0.001 | 1.04 (0.99–1.09) | 0.068 | |||
| L1CAM | 41/228 | 16/227 | ||||
| Negative (ref) | — | — | ||||
| Positive | 2.26 (0.88–9.29) | 0.08 | 4.03 (1.11–13.74) | 0.035 | ||
| Tumour grade | 41/228 | 16/227 | ||||
| Grade 1 and 2 (ref) | — | — | ||||
| Grade 3 | 1.84 (0.65–4.62) | 0.2 | 2.73 (0.75–8.85) | 0.1 | ||
| Histology | 41/228 | 16/227 | ||||
| Endometrioid (ref) | — | — | ||||
| Non-endometrioid | 1.56 (0.08–9.29) | 0.7 | 3.43 (0.17–24.53) | 0.3 | ||
| LVSI | 41/228 | 16/227 | ||||
| Negative (ref) | — | — | ||||
| positive | 2.64 (0.98–6.02) | 0.2 | 9.65 (2.99–30.00) | <0.001 | ||
| Stage (FIGO 2009) | 41/228 | 16/227 | ||||
| Stage I (ref) | — | — | ||||
| Stage II–IV | 2.20 (1.04–4.46) | 0.04 | 3.42 (1.17–10.33) | 0.024 | ||